Major recommendations for use of passive immunization for hematopoietic stem cell transplant (HSCT) recipients exposed to vaccine-preventable diseases.
| Preparation . | Recommendations for Use . | Rating . |
|---|---|---|
| Cytomegalovirus immunoglobulin | Not recommended for prophylaxis among HSCT recipients because of its lack of efficacy. | DI |
| Varicella-zoster immunoglobulin | Should be administered to VZV seronegative recipients ≈ 96 hours after close contact with a person with varicella or shingles if the HSCT recipient is at a) < 24 months after HSCT or b) ≈ 24 months after HSCT and still immunocompromised. | AII |
| Intramuscular immunoglobulin | Should be administered to hepatitis A-susceptible HSCT recipients who anticipate hepatitis A exposure (e.g., during travel to endemic areas) and for postexposure prophylaxis as indicated. Should also be administered after measles exposure among HSCT recipients who were not vaccinated against measles after HSCT. | BIII |
| Intravenous immunoglobulin | Can be administered to HSCT recipients with severe hypogammaglobulinemia (immunoglobulin G < 400 mg/dl) ≈ 100 days after HSCT to prevent bacterial infections | CIII |
| Preparation . | Recommendations for Use . | Rating . |
|---|---|---|
| Cytomegalovirus immunoglobulin | Not recommended for prophylaxis among HSCT recipients because of its lack of efficacy. | DI |
| Varicella-zoster immunoglobulin | Should be administered to VZV seronegative recipients ≈ 96 hours after close contact with a person with varicella or shingles if the HSCT recipient is at a) < 24 months after HSCT or b) ≈ 24 months after HSCT and still immunocompromised. | AII |
| Intramuscular immunoglobulin | Should be administered to hepatitis A-susceptible HSCT recipients who anticipate hepatitis A exposure (e.g., during travel to endemic areas) and for postexposure prophylaxis as indicated. Should also be administered after measles exposure among HSCT recipients who were not vaccinated against measles after HSCT. | BIII |
| Intravenous immunoglobulin | Can be administered to HSCT recipients with severe hypogammaglobulinemia (immunoglobulin G < 400 mg/dl) ≈ 100 days after HSCT to prevent bacterial infections | CIII |